Form 4: BioMarin Director Walbert Acquires 3,130 Shares of Common Stock
SEC Form 4 Filing
Director Timothy P Walbert acquired 3,130 shares of BioMarin Pharmaceutical Inc. common stock on February 24, 2025, through restricted stock units.
Summary
- On February 24, 2025, Timothy P Walbert, a director of BioMarin Pharmaceutical Inc., acquired 3,130 shares of common stock.
- The acquisition was in the form of restricted stock units.
- The price per share was $0, indicating a grant or award.
- Following the transaction, Walbert directly owns 3,130 shares of BioMarin common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock acquisition by a company director. The acquisition itself can be seen as mildly positive, but the filing is purely informational.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/24/2025 | Date of transaction: Acquisition of 3,130 shares of common stock. |
| 02/26/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.